World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders

Imagem de Miniatura
Arquivos
art_BANDELOW_World_Federation_of_Societies_of_Biological_Psychiatry_WFSBP_2023.PDF (663.67 KB)
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
BANDELOW, Borwin
ALLGULANDER, Christer
BALDWIN, David S.
COSTA, Daniel Lucas da Conceicao
DENYS, Damiaan
DILBAZ, Nesrin
DOMSCHKE, Katharina
ERIKSSON, Elias
FINEBERG, Naomi A.
HATTENSCHWILER, Josef
Citação
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, v.24, n.2, p.79-117, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aim This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (published in 2002, revised in 2008). Method A consensus panel of 33 international experts representing 22 countries developed recommendations based on efficacy and acceptability of available treatments. In total, 1007 RCTs for the treatment of these disorders in adults, adolescents, and children with medications, psychotherapy and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medications. Result This paper, Part I, contains recommendations for the treatment of panic disorder/agoraphobia (PDA), generalised anxiety disorder (GAD), social anxiety disorder (SAD), specific phobias, mixed anxiety disorders in children and adolescents, separation anxiety and selective mutism. Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line medications. Cognitive behavioural therapy (CBT) is the first-line psychotherapy for anxiety disorders. The expert panel also made recommendations for patients not responding to standard treatments and recommendations against interventions with insufficient evidence. Conclusion It is the goal of this initiative to provide treatment guidance for these disorders that has validity throughout the world.
Palavras-chave
Anxiety disorders, treatment, guideline, adolescents, children
URI
https://observatorio.fm.usp.br/handle/OPI/53064
Referências
  1. Agrawal N, 2019, THER ADV PSYCHOPHARM, V9, DOI 10.1177/2045125319862968
  2. Allgulander, 2022, PSYCH SCI SA, V5, P1
  3. Allgulander C, 2016, CURR OPIN PSYCHIATR, V29, P13, DOI 10.1097/YCO.0000000000000217
  4. Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P21
  5. Alonso J, 2007, J CLIN PSYCHIAT, V68, P3
  6. Alonso J, 2018, DEPRESS ANXIETY, V35, P195, DOI 10.1002/da.22711
  7. American Psychiatric Association [APA], 2013, DIAGNOSTIC STAT MANU
  8. Amore M, 1999, HUM PSYCHOPHARM CLIN, V14, P429, DOI 10.1002/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.3.CO;2-V
  9. ANDERSCH S, 1991, ACTA PSYCHIAT SCAND, V83, P18, DOI 10.1111/j.1600-0447.1991.tb03097.x
  10. Anderson RJ, 2002, INT J PSYCHIAT MED, V32, P235, DOI 10.2190/KLGD-4H8D-4RYL-TWQ8
  11. Bakish D, 1996, PSYCHOPHARMACOL BULL, V32, P135
  12. Bandelow B, 2018, BRIT J PSYCHIAT, V212, P333, DOI 10.1192/bjp.2018.49
  13. Bandelow Borwin, 2017, World J Biol Psychiatry, V18, P162, DOI 10.1080/15622975.2016.1190867
  14. Bandelow B, 2016, WORLD J BIOL PSYCHIA, V17, P321, DOI 10.1080/15622975.2016.1181783
  15. Bandelow B, 2015, DIALOGUES CLIN NEURO, V17, P327
  16. Bandelow B, 2015, INT CLIN PSYCHOPHARM, V30, P183, DOI 10.1097/YIC.0000000000000078
  17. Bandelow Borwin, 2002, World J Biol Psychiatry, V3, P171, DOI 10.3109/15622970209150621
  18. Bandelow B, 2008, WORLD J BIOL PSYCHIA, V9, P248, DOI 10.1080/15622970802465807
  19. Bankier B, 2004, PSYCHOSOM MED, V66, P645, DOI 10.1097/01.psy.0000138126.90551.62
  20. Barterian JA, 2018, J PSYCHIATR PRACT, V24, P2, DOI 10.1097/PRA.0000000000000284
  21. Andre EB, 2020, PHARMACOEPIDEM DR S, V29, P1201, DOI 10.1002/pds.4932
  22. Lepola UM, 1998, J CLIN PSYCHIAT, V59, P528, DOI 10.4088/JCP.v59n1006
  23. BLACK B, 1994, J AM ACAD CHILD PSY, V33, P1000, DOI 10.1097/00004583-199409000-00010
  24. Boudewyns PA, 1996, CLIN PSYCHOL PSYCHOT, V3, P185, DOI 10.1002/(SICI)1099-0879(199609)3:3<185::AID-CPP101>3.0.CO;2-0
  25. Bouman WP, 1998, INT J GERIATR PSYCH, V13, P12, DOI 10.1002/(SICI)1099-1166(199801)13:1<12::AID-GPS718>3.3.CO;2-6
  26. BOYER W, 1995, INT CLIN PSYCHOPHARM, V10, P45, DOI 10.1097/00004850-199503000-00006
  27. Brenes GA, 2003, PSYCHOSOM MED, V65, P963, DOI 10.1097/01.PSY.0000097339.75789.81
  28. Bunevicius R, 2006, CNS DRUGS, V20, P897, DOI 10.2165/00023210-200620110-00003
  29. BYSTRITSKY A, 1994, ANXIETY, V1, P287
  30. Cahill SP, 1999, J ANXIETY DISORD, V13, P5, DOI 10.1016/S0887-6185(98)00039-5
  31. Caldirola D, 2020, EXPERT OPIN PHARMACO, V21, P1699, DOI 10.1080/14656566.2020.1779220
  32. Carlson JS, 1999, J CHILD ADOL PSYCHOP, V9, P293, DOI 10.1089/cap.1999.9.293
  33. Liebowitz M R, 1987, Mod Probl Pharmacopsychiatry, V22, P141
  34. Cavaljuga Semra, 2003, Bosn J Basic Med Sci, V3, P27
  35. Chamberlain SR, 2021, CNS DRUGS, V35, P703, DOI 10.1007/s40263-021-00832-x
  36. CHARNEY DS, 1986, J CLIN PSYCHIAT, V47, P580
  37. Chen MH, 2016, PROG NEURO-PSYCHOPH, V70, P219, DOI 10.1016/j.pnpbp.2016.02.001
  38. Chen TR, 2019, J PSYCHIATR RES, V118, P73, DOI 10.1016/j.jpsychires.2019.08.014
  39. COHEN J, 1962, J ABNORM PSYCHOL, V65, P145, DOI 10.1037/h0045186
  40. COLEMAN JH, 1992, BRIT J PSYCHIAT, V160, P191, DOI 10.1192/bjp.160.2.191
  41. Costa DLD, 2013, J PSYCHIATR RES, V47, P1700, DOI 10.1016/j.jpsychires.2013.07.006
  42. Davies SJC, 2004, BRIT MED J, V328, P939, DOI 10.1136/bmj.328.7445.939
  43. de Lijster JM, 2017, CAN J PSYCHIAT, V62, P237, DOI 10.1177/0706743716640757
  44. Manassis K, 2016, EUR CHILD ADOLES PSY, V25, P571, DOI 10.1007/s00787-015-0794-1
  45. DENBOER JA, 1988, INT CLIN PSYCHOPHARM, V3, P59, DOI 10.1097/00004850-198801000-00005
  46. Devilly GJ, 1998, BEHAV THER, V29, P435, DOI 10.1016/S0005-7894(98)80042-7
  47. Driessen E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137864
  48. Driessen J, 2020, CHILD PSYCHIAT HUM D, V51, P330, DOI 10.1007/s10578-019-00933-1
  49. Driot D, 2016, THERAPIE, V71, P575, DOI 10.1016/j.therap.2016.04.006
  50. Ehlers A, 2014, AM J PSYCHIAT, V171, P294, DOI 10.1176/appi.ajp.2013.13040552
  51. Evoy KE, 2021, DRUGS, V81, P125, DOI 10.1007/s40265-020-01432-7
  52. Falkai P, 2005, WORLD J BIOL PSYCHIA, V6, P132, DOI 10.1080/15622970510030090
  53. Flint J, 2015, Psychol Med, V45, P439, DOI 10.1017/S0033291714001421
  54. Foa EB, 2018, JAMA-J AM MED ASSOC, V319, P354, DOI 10.1001/jama.2017.21242
  55. Mancuso CE, 2004, PHARMACOTHERAPY, V24, P1177, DOI 10.1592/phco.24.13.1177.38089
  56. Frasure-Smith N, 2008, ARCH GEN PSYCHIAT, V65, P62, DOI 10.1001/archgenpsychiatry.2007.4
  57. Freire RC, 2017, J CLIN PSYCHOPHARM, V37, P429, DOI 10.1097/JCP.0000000000000740
  58. Furukawa TA, 2014, ACTA PSYCHIAT SCAND, V130, P181, DOI 10.1111/acps.12275
  59. Furukawa TA., 2019, COCHRANE DB SYST REV, V6
  60. Gahr M, 2013, EUR J CLIN PHARMACOL, V69, P1335, DOI 10.1007/s00228-012-1464-6
  61. Gibbons RD, 2007, AM J PSYCHIAT, V164, P1356, DOI 10.1176/appi.ajp.2007.07030454
  62. Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701
  63. Goddard AW, 2001, ARCH GEN PSYCHIAT, V58, P681, DOI 10.1001/archpsyc.58.7.681
  64. Gomez AF, 2018, EXPERT OPIN PHARMACO, V19, P883, DOI 10.1080/14656566.2018.1472767
  65. GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
  66. Mataix-Cols D, 2016, WORLD PSYCHIATRY, V15, P80, DOI 10.1002/wps.20299
  67. Grigoriadis S, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f6932
  68. Guy E., 1976, ECDEU ASS MAN PSYCH, P217
  69. Halaby A, 2015, CURR DRUG SAF, V10, P184, DOI 10.2174/1574886309666141022101956
  70. HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x
  71. Hasan A, 2019, WORLD J BIOL PSYCHIA, V20, P2, DOI 10.1080/15622975.2018.1557346
  72. Heldt E, 2003, PSYCHOTHER PSYCHOSOM, V72, P43, DOI 10.1159/000067188
  73. Herring MP, 2012, PSYCHOTHER PSYCHOSOM, V81, P21, DOI 10.1159/000327898
  74. Hetrick S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004851.pub2
  75. Holt RIG, 2013, J AFFECT DISORDERS, V150, P84, DOI 10.1016/j.jad.2013.02.026
  76. Hrobjartsson A, 2013, CAN MED ASSOC J, V185, pE201, DOI 10.1503/cmaj.120744
  77. MAVISSAKALIAN M, 1992, ARCH GEN PSYCHIAT, V49, P318
  78. Huang YQ, 2019, LANCET PSYCHIAT, V6, P211, DOI 10.1016/S2215-0366(18)30511-X
  79. Issari Y, 2016, J CLIN PSYCHIAT, V77, pE605, DOI 10.4088/JCP.14r09758
  80. Johnson EM, 2006, AM J GERIAT PSYCHIAT, V14, P796, DOI 10.1097/01.JGP.0000204328.50105.b3
  81. Jones CW, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6104
  82. Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
  83. Kessler RC, 2007, WORLD PSYCHIATRY, V6, P168
  84. Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359
  85. KLEIN RG, 1992, J AM ACAD CHILD PSY, V31, P21, DOI 10.1097/00004583-199201000-00005
  86. Kopp S, 1997, J CHILD PSYCHOL PSYC, V38, P257, DOI 10.1111/j.1469-7610.1997.tb01859.x
  87. Lecrubier Y, 1997, ACTA PSYCHIAT SCAND, V95, P153, DOI 10.1111/j.1600-0447.1997.tb00389.x
  88. May T, 2020, INT J DRUG POLICY, V82, DOI 10.1016/j.drugpo.2020.102823
  89. Lepola U, 2003, J CLIN PSYCHIAT, V64, P654, DOI 10.4088/JCP.v64n0606
  90. LEPOLA U, 1990, Human Psychopharmacology, V5, P159, DOI 10.1002/hup.470050209
  91. Mbaya P, 2007, HUM PSYCHOPHARM CLIN, V22, P129, DOI 10.1002/hup.834
  92. McAllister-Williams RH, 2017, J PSYCHOPHARMACOL, V31, P519, DOI 10.1177/0269881117699361
  93. Mikkelsen RL, 2004, NORD J PSYCHIAT, V58, P65, DOI 10.1080/08039480310000824
  94. Bakker A, 1999, J CLIN PSYCHIAT, V60, P831, DOI 10.4088/JCP.v60n1205
  95. Moritz S, 2019, EUR ARCH PSY CLIN N, V269, P577, DOI 10.1007/s00406-018-0931-1
  96. NAGY LM, 1989, ARCH GEN PSYCHIAT, V46, P993
  97. Nardi AE, 2011, BRAZ J MED BIOL RES, V44, P366, DOI 10.1590/S0100-879X2011007500020
  98. Nardi AE, 2012, J CLIN PSYCHOPHARM, V32, P120, DOI 10.1097/JCP.0b013e31823fe4bd
  99. Nardi AE, 2010, J CLIN PSYCHOPHARM, V30, P290, DOI 10.1097/JCP.0b013e3181dcb2f3
  100. Nelson J, 1999, Can J Clin Pharmacol, V6, P69
  101. Nutt DJ, 2008, J PSYCHOPHARMACOL, V22, P3, DOI 10.1177/0269881107086283
  102. Nutt DJ, 2005, J PSYCHOPHARMACOL, V19, P123, DOI 10.1177/0269881105051987
  103. Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x
  104. Otto MW, 2001, AM J PSYCHIAT, V158, P1989, DOI 10.1176/appi.ajp.158.12.1989
  105. Bakker A, 1999, J AFFECT DISORDERS, V54, P189, DOI 10.1016/S0165-0327(98)00147-5
  106. OTTO MW, 1993, AM J PSYCHIAT, V150, P1485
  107. Perna G, 2001, PHARMACOPSYCHIATRY, V34, P85, DOI 10.1055/s-2001-14283
  108. Pollack MH, 2014, AM J PSYCHIAT, V171, P44, DOI 10.1176/appi.ajp.2013.12101353
  109. Pollack MH, 2003, J PSYCHOPHARMACOL, V17, P276, DOI 10.1177/02698811030173009
  110. POLLACK MH, 1994, J CLIN PSYCHIAT, V55, P200
  111. POLLACK MH, 1993, J CLIN PSYCHOPHARM, V13, P257
  112. Procyshyn, 2019, CLIN HDB PSYCHOTROPI
  113. Quagliato LA, 2019, J PSYCHOPHARMACOL, V33, P1340, DOI 10.1177/0269881119859372
  114. REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85
  115. RICKELS K, 1982, AM J PSYCHOTHER, V36, P358, DOI 10.1176/appi.psychotherapy.1982.36.3.358
  116. Baldwin DS, 2022, ADDICTION, V117, P1472, DOI 10.1111/add.15695
  117. RICKELS K, 1990, ARCH GEN PSYCHIAT, V47, P899
  118. RIZLEY R, 1986, PSYCHOPHARMACOL BULL, V22, P167
  119. Robinson L, 2020, PSYCHOTHER RES, V30, P79, DOI 10.1080/10503307.2019.1566676
  120. Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700
  121. ROMACH M, 1995, AM J PSYCHIAT, V152, P1161
  122. Roose SP, 2003, BIOL PSYCHIAT, V54, P262, DOI 10.1016/S0006-3223(03)00320-2
  123. Rubio G, 2007, ACTA PSYCHIAT SCAND, V115, P372, DOI 10.1111/j.1600-0447.2006.00896.x
  124. Rubio G, 2007, EUR PSYCHIAT, V22, P80, DOI 10.1016/j.eurpsy.2006.09.007
  125. Sartori SB, 2019, PHARMACOL THERAPEUT, V204, DOI 10.1016/j.pharmthera.2019.107402
  126. Scahill L, 2005, J CHILD ADOL PS NURS, V18, P86, DOI 10.1111/j.1744-6171.2005.00015.x
  127. Baldwin DS, 2009, HUM PSYCHOPHARM CLIN, V24, P269, DOI 10.1002/hup.1019
  128. Schiele MA, 2020, EUR NEUROPSYCHOPHARM, V33, P45, DOI 10.1016/j.euroneuro.2020.01.009
  129. Schneier FR, 2017, DEPRESS ANXIETY, V34, P1085, DOI 10.1002/da.22693
  130. Schwan S, 2010, EUR J CLIN PHARMACOL, V66, P947, DOI 10.1007/s00228-010-0853-y
  131. Schweizer E, 1998, PSYCHOL MED, V28, P713, DOI 10.1017/S0033291798006540
  132. Segool NK, 2008, DEPRESS ANXIETY, V25, P620, DOI 10.1002/da.20410
  133. SELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965
  134. Sharp SC, 2006, CLIN DRUG INVEST, V26, P247, DOI 10.2165/00044011-200626050-00002
  135. Shen BJ, 2008, J AM COLL CARDIOL, V51, P113, DOI 10.1016/j.jacc.2007.09.033
  136. Siegmann EM, 2018, JAMA PSYCHIAT, V75, P577, DOI 10.1001/jamapsychiatry.2018.0190
  137. Silberman E, 2021, BRIT J PSYCHIAT, V218, P125, DOI 10.1192/bjp.2020.164
  138. Bandelow B, 2007, PHARMACOPSYCHIATRY, V40, P152, DOI 10.1055/s-2007-984398
  139. Simon GE, 2006, AM J PSYCHIAT, V163, P41, DOI 10.1176/appi.ajp.163.1.41
  140. Skapinakis P, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20430
  141. Spiegel DA, 1999, J CLIN PSYCHOPHARM, V19, p17S, DOI 10.1097/00004714-199912002-00004
  142. Stein DJ, 2019, GLOBAL MENTAL HLTH P, V1st
  143. TAYLOR CB, 1990, J CLIN PSYCHOPHARM, V10, P112, DOI 10.1097/00004714-199004000-00006
  144. Turner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779
  145. Tyrer P, 2021, PSYCHOL MED, DOI 10.1017/S0033291721000878
  146. Tyrer PJ., 2010, ENCY PSYCHOPHARMACOL, P218
  147. UHLENHUTH EH, 1989, J AFFECT DISORDERS, V17, P261, DOI 10.1016/0165-0327(89)90009-8
  148. Varigonda AL, 2016, J AM ACAD CHILD PSY, V55, P851, DOI 10.1016/j.jaac.2016.07.768
  149. Bandelow B, 2004, J CLIN PSYCHIAT, V65, P405
  150. Wade AG, 1997, BRIT J PSYCHIAT, V170, P549, DOI 10.1192/bjp.170.6.549
  151. Watts SE, 2015, J AFFECT DISORDERS, V175, P152, DOI 10.1016/j.jad.2014.12.025
  152. Weathers FW, 2018, PSYCHOL ASSESSMENT, V30, P383, DOI 10.1037/pas0000486
  153. WHO, 2017, WHO 11 REV INT CLASS
  154. Wittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15, P357, DOI 10.1016/j.euroneuro.2005.04.012
  155. WOODS SW, 1992, J CLIN PSYCHOPHARM, V12, P32
  156. World Health Organization, 1993, ICD 10 CLASS MENT BE
  157. Worthington JJ, 1998, PSYCHOPHARMACOL BULL, V34, P199
  158. Yang LN, 2019, EUR CHILD ADOLES PSY, V28, P79, DOI 10.1007/s00787-018-1189-x
  159. Zhou XY, 2015, WORLD PSYCHIATRY, V14, P207, DOI 10.1002/wps.20217
  160. Bandelow B, 2001, CAN J PSYCHIAT, V46, P948, DOI 10.1177/070674370104601007
  161. Zohar J, 2014, EUR NEUROPSYCHOPHARM, V24, P1005, DOI 10.1016/j.euroneuro.2013.08.004
  162. Zomahoun HTV, 2017, INT J EPIDEMIOL, V46, P589, DOI 10.1093/ije/dyw273
  163. Bandelow B., 2003, HDB DEPRESSION ANXIE, P49
  164. Bandelow B., 1999, PANIC AGORAPHOBIA SC
  165. Bandelow B, 2023, WORLD J BIOL PSYCHIA, V24, P118, DOI 10.1080/15622975.2022.2086296
  166. Bandelow B, 2022, BMC PSYCHIATRY, V22, DOI 10.1186/s12888-022-04002-1
  167. Bandelow B, 2006, J CLIN PSYCHIAT, V67, P1428, DOI 10.4088/JCP.v67n0914
  168. Bandelow B, 2006, CNS SPECTRUMS, V11, P21, DOI 10.1017/S1092852900025815
  169. Bandelow B, 2022, EUR ARCH PSY CLIN N, V272, P571, DOI 10.1007/s00406-021-01324-1
  170. Bandelow B, 2021, EUR NEUROPSYCHOPHARM, V49, P116, DOI 10.1016/j.euroneuro.2021.04.012
  171. Bandelow B, 2020, ADV EXP MED BIOL, V1191, P347, DOI 10.1007/978-981-32-9705-0_19
  172. Bandelow B, 2020, EUR ARCH PSY CLIN N, V270, P655, DOI 10.1007/s00406-018-0972-5

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23